Evidence map›Paper›PMID 24842370›Full record

ArticleThe Journal of experimental medicine2014

Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4⁺ T cell tolerance.

Juan Dubrot, Fernanda V Duraes, Lambert Potin, Francesca Capotosti, Dale Brighouse, Tobias Suter, Salomé LeibundGut-Landmann, Natalio Garbi, Walter Reith, Melody A Swartz and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Lymphatic transport in anti-tumor immunity and metastasis.The Journal of experimental medicine · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Juan DubrotDepartment of Pathology and Immunology, University of Geneva Medical School, 1211 Geneva, Switzerland.
Fernanda V DuraesDepartment of Pathology and Immunology, University of Geneva Medical School, 1211 Geneva, Switzerland.
Lambert PotinLaboratory of Lymphatic and Cancer Bioengineering, Institute of Bioengineering and Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
Francesca CapotostiLaboratory of Lymphatic and Cancer Bioengineering, Institute of Bioengineering and Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
Dale BrighouseDepartment of Pathology and Immunology, University of Geneva Medical School, 1211 Geneva, Switzerland.
Tobias SuterDepartment of Neurology, Section of Neuroimmunology and MS Research, University Hospital Zurich, 8091 Zurich, Switzerland.
Salomé LeibundGut-LandmannInstitute of Microbiology, Swiss Federal Institute of Technology Zürich, 8093 Zurich, Switzerland.
Natalio GarbiInstitute of Molecular Medicine and Institute of Experimental Immunology, University of Bonn, 53105 Bonn, Germany Institute of Molecular Medicine and Institute of Experimental Immunology, University of Bonn, 53105 Bonn, Germany.
Walter ReithDepartment of Pathology and Immunology, University of Geneva Medical School, 1211 Geneva, Switzerland.
Melody A SwartzLaboratory of Lymphatic and Cancer Bioengineering, Institute of Bioengineering and Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland ISREC, SV, EPFL, 1015 Lausanne, Switzerland Stephanie.hugues@unige.ch melody.swartz@epfl.ch.
Stéphanie HuguesDepartment of Pathology and Immunology, University of Geneva Medical School, 1211 Geneva, Switzerland Stephanie.hugues@unige.ch melody.swartz@epfl.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dendritic cells (DCs), and more recently lymph node stromal cells (LNSCs), have been described to tolerize self-reactive CD8(+) T cells in LNs. Although LNSCs express MHCII, it is unknown whether they can also impact CD4(+) T cell functions. We show that the promoter IV (pIV) of class II transactivator (CIITA), the master regulator of MHCII expression, controls endogenous MHCII expression by LNSCs. Unexpectedly, LNSCs also acquire peptide-MHCII complexes from DCs and induce CD4(+) T cell dysfunction by presenting transferred complexes to naive CD4(+) T cells and preventing their proliferation and survival. Our data reveals a novel, alternative mechanism where LN-resident stromal cells tolerize CD4(+) T cells through the presentation of self-antigens via transferred peptide-MHCII complexes of DC origin.

Indexed as

AnimalsAntigen PresentationAntigensCD4-Positive T-LymphocytesCell ProliferationCells, CulturedDendritic CellsFlow CytometryGene ExpressionHistocompatibility Antigens Class IIImmune ToleranceInterferon-gammaLymph NodesMiceMice, Inbred C57BLMice, KnockoutAntigensHistocompatibility Antigens Class IIInterferon-gammaMHC class II transactivator proteinNuclear ProteinsPeptidesTrans-Activators

Identifiers

PMID24842370
PMCPMC4042642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.